9 completed, 3 unknown, 1 recruiting. 10 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Unknown 3 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow SHR4640: new trials by email Literature Review of SHR4640 trials Research Report on SHR4640
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia SHR4640 ï¼›Febuxostat, SHR4640 ; Febuxostat, SHR4640 - Primary Gout and Hyperuricemia | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 340 | 2026-02-09 | 2026-04-07 |
| Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects SHR4640 - Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 34 | 2023-12-13 | 2024-01-23 |
| Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects SHR4640 - Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 16 | 2023-08-07 | 2024-07-11 |
| A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout SHR4640, Allopurinol - Gout | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 779 | 2021-06-15 | 2025-01-24 |
| Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers SHR4640 - Healthy Subjects | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 14 | 2020-12-01 | 2020-11-09 |
| Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers SHR4640 - Primary Gout, Hyperuricemia | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2020-10-01 | 2020-10-14 |
| Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment SHR4640 - Hepatic Impairment | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2020-08-04 | 2022-08-10 |
| Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia Placebo, SHR4640, benzbromarone - Hyperuricemia | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 198 | 2017-07-20 | 2019-08-07 |
| Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level SHR4640 - Gout, Hyperuricemia | Phase 1 | Completed | Atridia Pty Ltd. | 24 | 2017-07-04 | 2018-03-21 |
| The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout Colchicine, Febuxostat, SHR4640 - Gout | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 15 | 2017-02-17 | 2019-08-08 |
| A Single Dose Study of SHR4640 in Healthy Male Volunteers SHR4640, Placebo - Gout | Phase 1 | Completed | Atridia Pty Ltd. | 40 | 2016-09-22 | 2018-07-03 |
| Multiple Dose Study of SHR4640 in Healthy Subjects SHR4640, placebo - Gout; Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 48 | 2016-07-01 | 2017-03-30 |
| Single Dose Study of SHR4640 in Healthy Subjects SHR4640, Placebo - Gout; Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 50 | 2015-11-01 | 2017-02-28 |
Hyperuricemia (8) · Gout (6)
Jiangsu HengRui Medicine Co., Ltd. (11) · Atridia Pty Ltd. (2)
China (9) · Australia (2)
Beibei Liang, PhD (1) · Chunde Bao (1) · Sam Salman, B.Sc,BMBS (1) · Sam Salman, B.Sc.BMBS (1) · Zourong Ruan, PhD (1)